New issues in genetic counseling of hereditary colon cancer

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages

  Lynch, Patrick M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB;

CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER SCREENING; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; COLON CANCER; COLORECTAL CANCER; CONFERENCE PAPER; ENDOSCOPY; FAMILIAL CANCER; GENETIC COUNSELING; HEALTH SERVICE; HUMAN; PRIORITY JOURNAL;

CLINICAL TRIALS AS TOPIC; COLONIC NEOPLASMS; COLONOSCOPY; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETIC COUNSELING; HEALTH EDUCATION; HUMANS;

EID: 36749054072     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1124     Document Type: Conference Paper

References (28)

1. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600.
2. Spirio L, Otterud B, Stauffer D, et al. Linkage of a variant or attenuated form of adenomatous polyposis coli to the adenomatous polyposis coli (APC) locus. Am J Hum Genet 1992;51:92-100.
3. Al-Tassen N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet 2002;30:227-32.
4. Peltomäki P, Aaltonen L, Sistonen P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993;260:810-2.
5. Lindblom A, Tannergard P, Werelius B, et al. Genetic mapping of a second locus predisposing to hereditary nonpolyposis colorectal cancer. Nat Genet 1993;5:279-82.
6. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defect in Peutz-Jeghers syndrome. Nature 1998;391:184-7.
7. Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18:38-43.
8. Houlston R, Bevan S, Williams A. Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of cases. Hum Mol Genet 1998;7:1907-12.
9. Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001;28:184-7.
10. Cotton R. The Human Variome Project. International collection of human gene variation. Available at: http://www.humanvariomeproject.org. Accessed February 6, 2007.
11. Balmana J, Stockwell DH, Steyerberg EW, et al. Prediction of MLH1 and MSH2 in Lynch syndrome. JAMA 2006;296:1469-78.
12. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006;296:1479-87.
13. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006;354:2751-63.
14. Ford JM, Whittemore AS. Predicting and preventing hereditary colorectal cancer. JAMA 2006;296:1521-3.
15. Hampel H, Frankel WL, Martin E et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-60.
16. Piñol V, Castells A, Andreu M et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005;293:1986-94.
17. Lynch HT, Boland CR, Rodriguez-Bigas MA, et al. Who should be sent for genetic testing in hereditary colorectal cancer syndromes. J Clin Oncol 2007;25:3534-42.
18. Winawer S, Fletcher R, Rex D, et al. Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: Clinical guidelines and rationale. Update based on new evidence. Gastroenterology 2003;124:544-60.
19. Levin B, Barthel JS, Burt RW, et al. Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw 2006;4:384-420.
20. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53:27-43.
21. Desch CE, Benson AB III, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23:8512-9.
22. Church J, Simmang C. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 2003;46:1001-12.
23. Hurlstone DP, Cross SS, Drew K, et al. An evaluation of colorectal endoscopic mucosa resection using high-magnification chromoscopic colonoscopy: a prospective study of 1000 colonoscopies. Endoscopy 2004;36:491-8.
24. Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006;24:4642-60.
25. Hawk ET, Umar A, Viner JL. Colorectal cancer chemoprevention - an overview of the science. Gastroenterology 2004;126:1423-47.
26. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-9.
27. Van Stolk R, Stoner G, Hayton WL, et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 2000;6:78-89.
28. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006;296:1507-17.